Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

Blade is adding to its fibrosis pipeline with the acquisition of PharmAkea-spinout ATXco Inc. and its autotaxin inhibitor PAT-409.

President and CEO Wendye Robbins said PAT-409 is complementary to Blade Therapeutics Inc.’s BLD-2660, a calpain inhibitor that reduces fibrosis via a different pathway.


Read the full 440 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers